It’s been a crucial week for Haemonetics Corporation (NYSE:HAE); here’s what analysts have to say.

June 17, 2018 - By Adrian Mccoy

Haemonetics Corporation (NYSE:HAE) LogoInvestors sentiment increased to 1.18 in Q1 2018. Its up 0.07, from 1.11 in 2017Q4. It increased, as 15 investors sold Haemonetics Corporation shares while 81 reduced holdings. 45 funds opened positions while 68 raised stakes. 49.88 million shares or 2.00% less from 50.89 million shares in 2017Q4 were reported.
Cap Research Investors invested in 1.22M shares or 0.03% of the stock. Clarivest Asset Management holds 0% in Haemonetics Corporation (NYSE:HAE) or 7 shares. Neuberger Berman Group Ltd Liability Corporation holds 1.74 million shares. Systematic Finance Lp has invested 0.03% in Haemonetics Corporation (NYSE:HAE). Assetmark has invested 0% in Haemonetics Corporation (NYSE:HAE). Acadian Asset Ltd Liability holds 691,943 shares or 0.22% of its portfolio. Janney Montgomery Scott Lc invested 0.03% in Haemonetics Corporation (NYSE:HAE). Koch Indus stated it has 4,422 shares. Tci Wealth Incorporated holds 0% in Haemonetics Corporation (NYSE:HAE) or 20 shares. Reilly Fincl Advisors Ltd owns 125 shares. Wisconsin-based Convergence Ptnrs Ltd Liability has invested 0.17% in Haemonetics Corporation (NYSE:HAE). Sei Company stated it has 0% of its portfolio in Haemonetics Corporation (NYSE:HAE). Nelson Van Denburg Campbell Wealth Grp Ltd Liability Company reported 0.06% stake. Baldwin Brothers Ma holds 0.18% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 15,610 shares. 33,273 were reported by Voya Limited Company.

Since January 2, 2018, it had 0 insider buys, and 9 sales for $1.14 million activity. Shares for $19,844 were sold by Scanlan Jacqueline on Thursday, June 7. Burke William P. Mr. had sold 425 shares worth $39,410. $28,097 worth of Haemonetics Corporation (NYSE:HAE) shares were sold by Basil Michelle L. 183 shares were sold by Ryding Neil Mr., worth $16,970. On Tuesday, January 2 KROLL MARK W sold $448,434 worth of Haemonetics Corporation (NYSE:HAE) or 7,118 shares. 3,794 Haemonetics Corporation (NYSE:HAE) shares with value of $360,766 were sold by Goldstein Dan.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 3 analysts covering Haemonetics Corp (NYSE:HAE), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Haemonetics Corp had 9 analyst reports since December 21, 2017 according to SRatingsIntel. As per Wednesday, February 7, the company rating was maintained by Jefferies. Morgan Stanley maintained it with “Overweight” rating and $77 target in Wednesday, February 7 report. The firm has “Buy” rating by Jefferies given on Thursday, December 21. Morgan Stanley maintained Haemonetics Corporation (NYSE:HAE) on Wednesday, March 28 with “Buy” rating. The company was upgraded on Tuesday, January 2 by Raymond James. The stock of Haemonetics Corporation (NYSE:HAE) has “Overweight” rating given on Tuesday, January 2 by Morgan Stanley. Jefferies maintained the shares of HAE in report on Thursday, June 14 with “Buy” rating. As per Monday, January 8, the company rating was maintained by Jefferies. The stock of Haemonetics Corporation (NYSE:HAE) has “Overweight” rating given on Wednesday, May 9 by Morgan Stanley. Below is a list of Haemonetics Corporation (NYSE:HAE) latest ratings and price target changes.

14/06/2018 Broker: Jefferies Old Rating: Buy New Rating: Buy Old Target: $95 New Target: $110 Maintain
09/05/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $77 New Target: $100 Maintain
28/03/2018 Broker: Morgan Stanley Rating: Buy Maintain
07/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $74 New Target: $77 Maintain
07/02/2018 Broker: Jefferies Rating: Buy New Target: $80.0 Maintain
08/01/2018 Broker: Jefferies Rating: Buy New Target: $75.0 Maintain
02/01/2018 Broker: Raymond James Old Rating: Underperform New Rating: Market Perform Upgrade
02/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
21/12/2017 Broker: Jefferies Rating: Buy New Target: $68.0 Maintain

The stock decreased 4.83% or $4.62 during the last trading session, reaching $91.13. About 8.51M shares traded or 1294.90% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 121.77% since June 17, 2017 and is uptrending. It has outperformed by 109.20% the S&P500.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $4.76 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It has a 107.21 P/E ratio. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

More news for Haemonetics Corporation (NYSE:HAE) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018. Seekingalpha.com‘s article titled: “S&P indexes swap firms due to shifting market caps; FSB to SmallCap 600” and published on June 08, 2018 is yet another important article.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: